A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

PURPOSE. Angiogenesis is an important hallmark of breast cancer growth and progression. Pazopanib, an oral small molecule inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and KIT, has activity across a range of solid tumors. We evaluated the activity...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Taylor, Sara K., Chia, Stephen, Dent, Susan, Clemons, Mark, Agulnik, Mark, Grenci, Pamela, Wang, Lisa, Oza, Amit M., Ivy, Percy, Pritchard, Kathleen I., Leighl, Natasha B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2010
Aiheet:
Breast Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228026/
https://ncbi.nlm.nih.gov/pubmed/20682606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0081
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia